RE:RE:RE:RE:RE:Back To Where It BelongsBack to Xebec yet again.
A remarkably unusual story that I'm seriously considering writing a book about.
Referring to Xebec is the best you can do.
It's all you've ever done.
It's all anyone here has done.
That aside, all my posts here on Stockhouse in the past year have either been bullish on Exro, which I first mentioned here in November at $1.21, and which has essentially doubled after first almost tripling in 4 months, or.bearish on pyrogenesis, which has since lost 2/3rds of its value.
Maybe I should write a book about pyrogenesis instead of Xebec .
They're both Canadian business disasters, for very different reasons.
Incidentally, Xebec was trading at $0.51 when it was.halted and was cap'd at $80 million. There were 5 analysts covering it and the concensus target was ~ $2.25. I believe the National bank's analysist's target was $3. (Ie market cap $500 million ) Also, I first recommended Xebec at 47 cents in 2017. $47,000 grew to a high of 1,150,000 in less than four years before it imploded. RBC 's analyst raised his target to $17.5 on January 14th, 2021.
Pyrogenesis isn't followed by a single analyst at a Canadian bank.
Not one single analyst.
I.won't talk about Xebec here again..
And you know absolutely nothing about Xebec compared to what I know.
You only know it failed.
The only reason you bring it up.